Clinical Trials List
2020-09-30 - 2029-01-09
Phase I/II
Recruiting2
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 劉奕廷 無
- Chiu Hung Chiu Division of General Internal Medicine
- Yih-Jyh Lin Division of General Surgery
- Shang-Yin Wu 無
- 簡世杰 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YU-YUN SHAO 無
- Ann-Lii Cheng 無
- 呂理駿 無
- Chia-Yu Chu Division of Dermatology
- Ying-Chun Shen 無
- Chiun Hsu 無
- 莊建淮 Division of Hematology & Oncology
- 林宗哲 無
- TSUNG-HAO LIU 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
518 participants
